Mouse Anti-NLRC5 Recombinant Antibody (B-10) (CBMAB-N2676-WJ)

Name: Mouse Anti-NLRC5 Recombinant Antibody (B-10)
SKU: CBMAB-N2676-WJ
Rating: 5 (1 reviews)

See all NLRC5 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

B-10

Application

WB, IP, IF, ELISA

Specificity

Mouse, Rat

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

NLR family, CARD domain containing 5

Introduction

This gene encodes a member of the caspase recruitment domain-containing NLR family. This gene plays a role in cytokine response and antiviral immunity through its inhibition of NF-kappa-B activation and negative regulation of type I interferon signaling pathways. [provided by RefSeq, Oct 2011]

Entrez Gene ID

Mouse	434341
Rat	291861

UniProt ID

Mouse	C3VPR6
Rat	M0R4M1

Alternative Names

NLR Family CARD Domain Containing 5; Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And CARD Domain Containing 5; Nucleotide-Binding Oligomerization Domain Protein 4; Caterpiller Protein 16.1; NOD-Like Receptor C5; CLR16.1;

Function

Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms.

Biological Process

Defense response to virusManual Assertion Based On ExperimentIEP:UniProtKB
Innate immune responseManual Assertion Based On ExperimentIMP:UniProtKB
Intracellular signal transductionManual Assertion Based On ExperimentIBA:GO_Central
Negative regulation of NF-kappaB transcription factor activityManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of type I interferon-mediated signaling pathwayManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of interferon-gamma-mediated signaling pathwayManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of MHC class I biosynthetic processManual Assertion Based On ExperimentIDA:BHF-UCL
Positive regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:BHF-UCL
Positive regulation of type I interferon-mediated signaling pathwayManual Assertion Based On ExperimentIDA:UniProtKB
Regulation of kinase activityManual Assertion Based On ExperimentIDA:UniProtKB

Cellular Location

Cytoplasm

Zhan, L., Zhang, J., Zhang, J., Liu, X., Zhu, S., Shi, Y., ... & Cao, Y. (2022). LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer. Cancer letters, 529, 37-52.

Yoshihama, S., Cho, S. X., Yeung, J., Pan, X., Lizee, G., Konganti, K., ... & Kobayashi, K. S. (2021). NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Scientific reports, 11(1), 3258.

Cho, S. X., Vijayan, S., Yoo, J. S., Watanabe, T., Ouda, R., An, N., & Kobayashi, K. S. (2021). MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology, 162(3), 252-261.

Shukla, A., Cloutier, M., Appiya Santharam, M., Ramanathan, S., & Ilangumaran, S. (2021). The MHC class-I transactivator NLRC5: implications to cancer immunology and potential applications to cancer immunotherapy. International Journal of Molecular Sciences, 22(4), 1964.

Tang, F., Xu, Y., & Zhao, B. (2020). NLRC5: new cancer buster?. Molecular Biology Reports, 47(3), 2265-2277.

Liu, Y. R., Yang, L., Xu, Q. Q., Lu, X. Y., Ma, T. T., Huang, C., & Li, J. (2019). Long noncoding RNA MEG3 regulates rheumatoid arthritis by targeting NLRC5. Journal of cellular physiology, 234(8), 14270-14284.

Luan, P., Jian, W., Xu, X., Kou, W., Yu, Q., Hu, H., ... & Peng, W. (2019). NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ. Nature communications, 10(1), 2882.

Wu, Y., Shi, T., & Li, J. (2019). NLRC5: A paradigm for NLRs in immunological and inflammatory reaction. Cancer letters, 451, 92-99.

Wang, J. Q., Liu, Y. R., Xia, Q., Chen, R. N., Liang, J., Xia, Q. R., & Li, J. (2019). Emerging roles for NLRC5 in immune diseases. Frontiers in Pharmacology, 10, 1352.

Wang, M., Wang, L., Fang, L., Li, S., & Liu, R. (2019). NLRC5 negatively regulates LTA‐induced inflammation via TLR2/NF‐κB and participates in TLR2‐mediated allergic airway inflammation. Journal of Cellular Physiology, 234(11), 19990-20001.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-NLRC5 Recombinant Antibody (B-10)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry